| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Abbott, Iain
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (1/1 displayed)
Places of action
| Organizations | Location | People |
|---|
article
Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic <i>In Vitro</i> Model
Abstract
<jats:p>There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant<jats:italic>Enterococcus</jats:italic>(VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility. We undertook pharmacodynamic profiling of fosfomycin against<jats:named-content content-type="genus-species">E. faecalis</jats:named-content>and<jats:named-content content-type="genus-species">E. faecium</jats:named-content>isolates using a dynamic<jats:italic>in vitro</jats:italic>bladder infection model. Eighty-four isolates underwent fosfomycin agar dilution susceptibility testing (<jats:named-content content-type="genus-species">E. faecalis</jats:named-content>MIC<jats:sub>50/90</jats:sub>32/64 μg/ml;<jats:named-content content-type="genus-species">E. faecium</jats:named-content>MIC<jats:sub>50/90</jats:sub>64/128 μg/ml).</jats:p>